
News|Articles|November 15, 2012
Testimony: FDA Commissioner says FDA has limited authority over compounding pharmacies to prevent meningitis outbreak
FDA Commissioner Margaret Hamburg was asked if the fungal meningitis outbreak could have been prevented by FDA during a 4-hour hearing Nov. 14 headed by the chairman of the House Energy and Commerce oversight subcommittee. Her answer was that FDA had limited authority because the New England Compounding Center (NECC), Framingham, Mass., was a ?compounding pharmacy,? which is regulated by the state Board of Pharmacy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
TrumpRx launches; some experts question its long-term value
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5

























